PT - JOURNAL ARTICLE AU - Eric D. Laing AU - Spencer L. Sterling AU - Stephanie A. Richard AU - Nusrat J. Epsi AU - Si’Ana Coggins AU - Emily C. Samuels AU - Shreshta Phogat AU - Lianying Yan AU - Nicole Moreno AU - Christian L. Coles AU - Matthew Drew AU - Jennifer Mehalko AU - Caroline E. English AU - Scott Merritt AU - Katrin Mende AU - Vincent J. Munster AU - Emmie de Wit AU - Kevin K. Chung AU - Eugene V. Millar AU - David R. Tribble AU - Mark P. Simons AU - Simon D. Pollett AU - Brian K. Agan AU - Dominic Esposito AU - Charlotte Lanteri AU - G. Travis Clifton AU - Edward Mitre AU - Timothy H. Burgess AU - Christopher C. Broder TI - Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses AID - 10.1101/2021.02.10.21251518 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.10.21251518 4099 - http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251518.short 4100 - http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251518.full AB - Sensitive and specific SARS-CoV-2 antibody assays remain critical for community and hospital-based SARS-CoV-2 sero-surveillance. With the rollout of SARS-CoV-2 vaccines, such assays must be able to distinguish vaccine from natural immunity to SARS-CoV-2 and related human coronaviruses. Here, we developed and implemented multiplex microsphere-based immunoassay strategies for COVD-19 antibody studies that incorporates spike protein trimers of SARS-CoV-2 and the endemic seasonal human coronaviruses (HCoV), enabling high throughout measurement of pre-existing cross-reactive antibodies. We varied SARS-CoV-2 antigen compositions within the multiplex assay, allowing direct comparisons of the effects of spike protein, receptor-binding domain protein (RBD) and nucleocapsid protein (NP) based SARS-CoV-2 antibody detection. Multiplex immunoassay performance characteristics are antigen-dependent, and sensitivities and specificities range 92-99% and 94-100%, respectively, for human subject samples collected as early as 7-10 days from symptom onset. SARS-CoV-2 spike and RBD had a strong correlative relationship for the detection of IgG. Correlation between detectable IgG reactive with spike and NP also had strong relationship, however, several PCR-positive and spike IgG-positive serum samples were NP IgG-negative. This spike and NP multiplex immunoassay has the potential to be useful for differentiation between vaccination and natural infection induced antibody responses. We also assessed the induction of de novo SARS-CoV-2 IgG cross reactions with SARS-CoV and MERS-CoV spike proteins. Furthermore, multiplex immunoassays that incorporate spike proteins of SARS-CoV-2 and HCoVs will permit investigations into the influence of HCoV antibodies on COVID-19 clinical outcomes and SARS-CoV-2 antibody durability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been funded by the Defense Health Program, U.S. DoD, under award HU0001190002 and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072. This project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E. VJM and EdW are supported by the Intramural Research Program of the National Institutes of Allergy and Infectious Diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The referenced human subjects protocols (IDCRP-045, IDCRP-085, and CAMP-NYC) were approved by the Uniformed Services University Institutional Review Board and participating sites. All subjects provided written or verbal informed consent using approved documents and procedures; the consent forms include clauses allowing use of specimens for investigations including those conducted in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.